Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VX1.DE
STRONG BUYFLAGVertex Pharmaceuticals Incorporated · Healthcare · United States · $127.2B · Avg Vol: $40K/d
89
StockRankGet insider-trade alerts
Q
79
V
29
M
80
P/E (TTM)
28.4x
ROE
24.2%
D/E
0.1x
Dividend %
—
AI CONVICTION THESIS
Vertex Pharmaceuticals has Q78 M82 but value at V28 is far below the calibrated floor. A dominant cystic fibrosis franchise with genuine pricing power, fully valued.
COMPANY DESCRIPTION
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.9B | 8.7B | 9.7B | 10.6B | 10.4% | 10.7B | 11.5B | 12.6B | 9.4% |
| EPS (EUR) | 11.40 | 12.35 | -1.83 | 13.59 | 6.0% | 14.82 | — | — | — |
| Shares | 257.0M | 257.7M | 256.9M | 254.0M | -1.2% | 253.8M | — | — | — |
| Debt | 790.9M | 710.7M | 1.5B | 1.8B | 31.2% | 1.7B | — | — | — |
| Equity | 12.2B | 15.5B | 14.4B | 16.4B | 10.3% | — | — | — | — |
| Op CF | 3.6B | 3.1B | -433.0M | 3.2B | -4.2% | 3.7B | — | — | — |
| Inv CF | -282.3M | -2.8B | -3.3B | -831.1M | — | — | — | — | — |
| Fin CF | -59.5M | -494.2M | -1.3B | -2.0B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+9.1%
SMA 50SMA 200
Close
$490.27
RSI (14)
56.5
52W High
$527.81
From 52W High
0.9%
SCORE BREAKDOWN
Quality
79
ROIC
21.4%92.6
ROE
24.2%91.6
GP/Assets
25.9%59.8
Op. Margin
38.1%96.1
FCF/Assets
12.5%90.8
Piotroski
668.3
Int. Cover
50.0x88.8
D/E Ratio
0.10x62.6
Current Ratio
3.02x54.0
Value
29
P/E (TTM)
28.4x40.6
EV/EBITDA
23.5x24.7
P/FCF
39.8x33.8
P/B
7.2x17.7
P/S
9.9x27.2
Div Yield
—N/A
Momentum
80
52W High %
93%88.5
RS 6M
4%75.4
SMA 50/200
1.05x74.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
60%78.1
FUNDAMENTALS
Market Cap
$127.2B
P/E (Forward)
—
Gross Margin
54.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VX1.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated(you) | $127.2B | 89 | STRONG BUY |
| REGN | Regeneron Pharmaceuticals, Inc. | $68.8B | 84 | STRONG BUY |
| 688235.SS | BeOne Medicines AG | $46.1B | 78 | BUY |
| ARGX | argenx SE | $57.1B | 70 | BUY |
| 0J9P.L | Incyte Corporation | $20.6B | 88 | STRONG BUY |
| 2269.HK | WuXi Biologics (Cayman) Inc. | $17.3B | 88 | STRONG BUY |
| UCB.BR | UCB SA | $56.0B | 64 | HOLD |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 88 | STRONG BUY |
| RPRX | Royalty Pharma plc | $33.9B | 70 | BUY |
| 0R2B.L | Danaher Corporation | $138.7B | 45 | HOLD |
Peer medians: ROE 2.1% · P/E 23.5x · Gross margin 50.2%